BCG vaccine for people with radiologically isolated syndrome
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests whether a BCG vaccine can help people who have radiologically isolated syndrome (RIS), a condition where MRI scans show signs of possible multiple sclerosis before symptoms develop. The study aims to see if vaccination is safe and can change disease behavior over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are over 18 years old and able to legally consent to the study
- You were diagnosed with radiologically isolated syndrome (RIS) within the last 5 years
- You are not pregnant and not breastfeeding
- You have not taken medicines that strongly weaken or change the immune system in the last 5 years (short, occasional steroid use is sometimes allowed)
- You can complete required medical tests and procedures, including MRI scans
- You have not had organ or bone marrow transplant, and you are not allergic to the vaccine ingredients
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well BRIUMVI (a medicine for relapsing multiple sclerosis) works for people in everyday life. Researchers want to see how people do when they first start the medication.
This study tests whether an mRNA vaccine (mRNA-1195) can help prevent relapses in people with early relapsing multiple sclerosis (MS). It compares the vaccine to a placebo (a shot with no active ingredient) to see if it is safe and effective.
This early phase trial tests a new treatment called GC012F for people with multiple sclerosis. It aims to see how safe and tolerable it is, and may offer a new option for those whose current treatments are not working well enough.
This trial tests a natural substance called Calculus Bovis Sativus (CBS) to see if it helps people with certain inflammatory brain conditions like multiple sclerosis, neuromyelitis optica, MOGAD, or ADEM. The goal is to find out if it is safe and effective.
This study uses artificial intelligence to help doctors better manage MS care. It uses MRI scans and a phone app to track your condition over time.
This study tests a new treatment called SYS6020 for people with multiple sclerosis (MS) that has not improved with standard therapies. The treatment aims to reduce MS activity and disability progression.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.